Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kymriah (tisagenlecleucel)
Pharma
FDA wants classwide boxed warning on existing CAR-Ts
The FDA contends that the risk of secondary T-cell cancer should be included in the label for all BCMA- and CD19-directed autologous T-cell therapies.
Angus Liu
Jan 23, 2024 3:27am
Cell therapy bigwigs endorse CAR-T in Nature Medicine article
Jan 9, 2024 5:00am
Novartis hit with FDA letter over manufacturing of CAR-T Kymriah
Dec 7, 2023 9:23am
England's NICE endorses Gilead's CAR-T Yescarta—finally
Jan 26, 2023 8:20am
FDA signs off on Roche's Lunsumio to treat follicular lymphoma
Dec 27, 2022 10:27am
Novartis' CAR-T Kymriah posts impressive survival data in ALL
Jun 13, 2022 11:38am